Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
03 Agosto 2020 - 8:00AM
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical
Officer
Oxurion NV appoints Grace Chang, M.D.,
Ph.D. as Chief Medical Officer
Key appointment as Oxurion progresses the
clinical development ofTHR-149 and THR-687
building innovative Diabetic Macular Edema (DME) therapy
franchise
Leuven, Belgium , 03 August 2020 – 08.00
CET – Oxurion NV (Euronext Brussels: OXUR), a
biopharmaceutical company engaged in the development of
next-generation therapies to treat diabetic eye disease, with a
focus on diabetic macular edema, today announces the
appointment of Grace Chang, M.D., Ph.D. as the company’s Chief
Medical Officer, effective August 1, 2020.
Dr. Chang is a board-certified ophthalmologist
and practicing vitreoretinal surgeon with deep expertise in
ophthalmic drug research and development. She will be responsible
for leading the Company’s clinical programs for both THR-687 and
THR-149 as Oxurion looks to build a world-leading diabetic macular
edema (DME) franchise that could provide much improved therapeutic
solutions for all DME patients.
Dr. Chang joins Oxurion from Notal Vision Inc,
where she held the position of CMO and was responsible for the
scientific and clinical strategy, clinical development and medical
affairs programs. She is currently an Adjunct Clinical Associate
Professor in the Department of Ophthalmology, Vitreoretinal Service
at the University of Southern California in Los Angeles, CA.
Prior to this, Dr. Chang held several high-level
clinical and strategic roles at Alcon Laboratories, a former
subsidiary of Novartis, following a faculty appointment at the
University of Washington.
Dr. Chang completed her ophthalmology residency
and vitreoretinal fellowship at Harvard Medical School,
Massachusetts Eye and Ear Infirmary in Boston, MA. Additionally,
Dr. Chang earned her M.D. from Stanford University, Stanford,
CA.
“I am thrilled to be joining Oxurion at such an
important point in the company’s development and I look forward to
leading the clinical trials of THR-149 and THR-687, two novel
molecules targeting DME with modes of action different from
anti-VEGFs.” said Dr. Grace Chang. “DME is a
leading cause of adult visual loss in developed countries, and new
approaches are urgently needed for patients including those who do
not respond optimally to anti-VEGF therapy. As a practicing
vitreoretinal surgeon, I am excited about THR-687 and THR-149 and
their potential to satisfy the needs of all patients with DME.”
Patrik De Haes, M.D., CEO of Oxurion,
said “I am delighted to welcome Grace as a member of our
senior leadership team. Her first-hand clinical experience and
development knowledge paired with her proven leadership skills come
at a critical time as we begin the Phase 2 development of our
DME-focused pipeline. We have developed clear target product
profiles for both THR-687 and THR-149 that together give us great
confidence that we will be able to develop a DME franchise that
will provide improved treatment options for all patients. This is
an exciting time for Oxurion as we look to generate the clinical
data needed to demonstrate the potential of our emerging DME
franchise.”
Oxurion’s emerging DME franchise will be based
on the successful development of both THR-149 and THR-687, two
novel therapeutics with different modes of action designed for
specific complementary target patient groups.
THR-149, a plasma kallikrein inhibitor, is being
developed to potentially become the treatment of choice for DME
patients with persistent edema who are currently sub-optimally
responding to anti-VEGF therapy.
Oxurion’s second drug candidate, THR-687, is a
best-in-class pan-RGD integrin antagonist holding potential to
become the standard of care for treatment-naïve patients by
replacing anti-VGEF’s as the mainstay of DME therapy.
Oxurion is confident that with both THR-687 and
THR-149 it will be able to provide new, tailored therapeutic
solutions that deliver improved clinical outcomes to almost all DME
patients.
END
For further information please
contact:
Oxurion NVWouter Piepers, Global Head of Investor Relations&
Corporate CommunicationsTel: +32 16 75 13 10 / +32 478 33 56
32wouter.piepers@oxurion.com |
Citigate Dewe Rogerson David Dible/ Sylvie Berrebi/Frazer HallTel:
+44 20 7638 9571oxurion@citigatedewerogerson.com |
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation ophthalmic
therapies which are designed to better preserve vision in patients
with diabetic macular edema (DME), the leading cause of vision loss
in diabetic patients worldwide.
Oxurion is building a leading global franchise
in the treatment of DME based on the successful development of its
two novel therapeutics:
- THR-149, a plasma kallikrein inhibitor is being developed as a
potential new standard of care for DME patients who respond
sub-optimally to anti-VEGF
therapy. THR-149
has shown positive Phase 1 results for the treatment of DME. The
Company is currently preparing to conduct a Phase 2 clinical
program which is now expected to start as soon as COVID-19 related
safety considerations allow an efficient study. THR-149 was
developed in conjunction with Bicycle Therapeutics PLC (NASDAQ:
BCYC).
- THR-687, a pan-RGD integrin inhibitor, is initially being
developed as a potential new standard of care for all DME
patients Positive
topline results from a Phase 1 clinical study assessing THR-687 as
a treatment for DME were announced in January 2020. THR-687 is
expected to enter a Phase 2 clinical trial in H1 2021. THR-687 is
an optimized compound derived from a broader library of integrin
inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ:
GLPG).
Oxurion is headquartered in Leuven, Belgium and
is listed on the Euronext Brussels exchange under the symbol OXUR.
More information is available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No
securities of Oxurion may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. state securities laws.
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Oxurion NV (EU:OXUR)
Storico
Da Apr 2023 a Apr 2024